
    
The LRRK2 gene encodes for leucine-rich repeat kinase 2, a serine-threonine protein kinase that belongs to the ROCO protein family and plays a significant role in various cellular processes, including the immune response and autophagy. The c.6055G>A p.Gly2019Ser rs34637584 variant in the LRRK2 gene, commonly referred to as p.G2019S, is a missense mutation that results in the substitution of glycine with serine at position 2019 of the protein. This variant has been widely associated with Parkinson's disease (PD) and is known to increase kinase activity of LRRK2, which is implicated in the pathogenesis of the disease [1][2][3][4][5].The p.G2019S variant is particularly prevalent in certain populations, accounting for over 30% of PD cases in Tunisian Arab-Berber individuals and is also common in Ashkenazi Jews and North African Arab-Berbers. It has been suggested that carriers of this variant are descendants of a common ancestral founder, with the allele estimated to have originated at least 40 generations ago. The variant demonstrates incomplete penetrance and variable expressivity, which indicates that other genetic or environmental factors may modulate the clinical manifestation of PD in carriers [1].In addition to its association with PD, the p.G2019S variant has been linked to an elevated risk of certain cancers, including colon cancer. Experimental models have shown that the variant promotes pathogenesis of colon cancer, characterized by increased tumor number and size, and enhances intestinal epithelial cell proliferation and inflammation within the tumor microenvironment [2].At the cellular level, the p.G2019S variant has been shown to induce mitochondrial DNA damage and affect mitochondrial dynamics, which may contribute to the neurodegenerative processes observed in PD. The variant also influences the structure-function relationships in human cortical neural networks, leading to aberrant morphology and heightened metabolic demand [3][5].Furthermore, the LRRK2 p.G2019S variant has been implicated in the immune response, with carriers showing increased levels of pro-inflammatory cytokines. It is hypothesized that the variant's impact on the innate immune system may influence the penetrance of PD, as LRRK2 is highly expressed in immune cells and can be induced upon stimulation with pro-inflammatory signals or pathogen exposure [1].Overall, the c.6055G>A p.Gly2019Ser rs34637584 variant in the LRRK2 gene is a significant genetic factor in PD, with implications for immune system function and potential links to cancer pathogenesis. The variant's high prevalence in specific populations and its impact on kinase activity make it a focal point for understanding the genetic underpinnings of PD and exploring targeted therapeutic interventions [1][2][3][4][5].

LRRK2遺伝子は、ロイシンリッチリピートキナーゼ2（leucine-rich repeat kinase 2）をコードしており、ROCOタンパク質ファミリーに属するセリン-スレオニンタンパク質キナーゼです。この遺伝子は、免疫応答やオートファジーを含むさまざまな細胞プロセスにおいて重要な役割を果たしています。LRRK2遺伝子のc.6055G>A p.Gly2019Ser rs34637584変異（一般的にp.G2019Sと呼ばれる）は、タンパク質の2019番目の位置でグリシンがセリンに置換されるミスセンス変異です。この変異はパーキンソン病（PD）と広く関連付けられており、LRRK2のキナーゼ活性を増加させることが知られており、病気の病因に関与しているとされています[1][2][3][4][5]。

p.G2019S変異は特定の集団で特に多く見られ、チュニジアのアラブ・ベルベル人ではPD症例の30%以上を占めています。また、アシュケナージ系ユダヤ人や北アフリカのアラブ・ベルベル人でも一般的です。この変異を持つキャリアは共通の祖先に由来すると考えられており、このアレルは少なくとも40世代前に起源を持つと推定されています。この変異は不完全浸透性と可変表現性を示しており、キャリアにおけるPDの臨床的発現には他の遺伝的または環境的要因が影響を与える可能性があることを示唆しています[1]。

PDとの関連に加えて、p.G2019S変異は結腸癌を含む特定の癌のリスク上昇とも関連付けられています。実験モデルでは、この変異が結腸癌の病因を促進し、腫瘍の数とサイズの増加、腸上皮細胞の増殖、および腫瘍微小環境内の炎症を引き起こすことが示されています[2]。

細胞レベルでは、p.G2019S変異はミトコンドリアDNA損傷を誘発し、ミトコンドリアのダイナミクスに影響を与えることが示されており、これがPDで観察される神経変性プロセスに寄与している可能性があります。この変異はまた、人間の皮質神経ネットワークにおける構造と機能の関係に影響を与え、異常な形態と代謝需要の増加を引き起こします[3][5]。

さらに、LRRK2 p.G2019S変異は免疫応答にも関与しており、キャリアは炎症性サイトカインのレベルが増加していることが示されています。この変異が自然免疫系に与える影響がPDの浸透性に影響を与える可能性があると仮定されており、LRRK2は免疫細胞で高く発現しており、炎症性シグナルや病原体への曝露によって誘導される可能性があります[1]。

全体として、LRRK2遺伝子のc.6055G>A p.Gly2019Ser rs34637584変異は、PDにおける重要な遺伝的要因であり、免疫系機能への影響や癌の病因との潜在的な関連を持っています。この変異の特定の集団における高い頻度とキナーゼ活性への影響は、PDの遺伝的基盤を理解し、標的を絞った治療介入を探る上で重要な焦点となっています[1][2][3][4][5]。
    
## References
- [1] Guenther DT et al. (2024). "The Evolution of Genetic Variability at the LRRK2 Locus." Genes, 15(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39062657/)
- [2] Wang Y et al. (2024). "LRRK2 G2019S Promotes Colon Cancer Potentially via LRRK2-GSDMD Axis-Mediated Gut Inflammation." Cells, 13(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38607004/)
- [3] Pena N et al. (2024). "G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage." NPJ Parkinson's disease, 10(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38429321/)
- [4] Ngo HKC et al. (2024). "Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons." Research square, () [PubMed](https://pubmed.ncbi.nlm.nih.gov/38562908/)
- [5] Valderhaug VD et al. (2024). "Micro-and mesoscale aspects of neurodegeneration in engineered human neural networks carrying the LRRK2 G2019S mutation." Frontiers in cellular neuroscience, 18() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38644975/)
- [6] Wang K et al. (2016). "Efficient Generation of Orthologous Point Mutations in Pigs via CRISPR-assisted ssODN-mediated Homology-directed Repair." Molecular therapy. Nucleic acids, 5(11) [PubMed](https://pubmed.ncbi.nlm.nih.gov/27898095/)
- [7] James NG et al. (2012). "Number and brightness analysis of LRRK2 oligomerization in live cells." Biophysical journal, 102(11) [PubMed](https://pubmed.ncbi.nlm.nih.gov/22713584/)
- [8] Mestre-Frances N et al. (2018). "Exogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman primate." JCI insight, 3(14) [PubMed](https://pubmed.ncbi.nlm.nih.gov/30046008/)
- [9] di Caudo C et al. (2020). "CAV-2-Mediated GFP and LRRK2(G2019S) Expression in the Macaca fascicularis Brain." Frontiers in molecular neuroscience, 13() [PubMed](https://pubmed.ncbi.nlm.nih.gov/32269512/)
- [10] Sun X et al. (2024). "Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study." Clinical and translational science, 17(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38266062/)
- [11] Barreh GA et al. (2024). "The Impact of LRRK2 G2019S on Parkinson's Disease: Clinical Phenotype and Treatment in Tunisian Patients." Journal of movement disorders, 17(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38649328/)
- [12] Elhadi A et al. (2024). "Multi-method computational evaluation of the inhibitors against leucine-rich repeat kinase 2 G2019S mutant for Parkinson's disease." Molecular diversity, 28(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38396210/)
- [13] Iovino L et al. (2024). "Investigation of microglial diversity in a LRRK2 G2019S mouse model of Parkinson's disease." Neurobiology of disease, 195() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38527708/)
- [14] Kmiecik MJ et al. (2024). "Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant." Brain : a journal of neurology, 147(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38804604/)
- [15] Guevara CA et al. (2024). "Parkinson's LRRK2-G2019S risk gene mutation drives sex-specific behavioral and cellular adaptations to chronic variable stress." bioRxiv : the preprint server for biology, () [PubMed](https://pubmed.ncbi.nlm.nih.gov/38895277/)

    
## ClinVar Submissions
- **[RCV000002017](https://www.ncbi.nlm.nih.gov/clinvar/RCV000002017/)**: Autosomal dominant Parkinson disease 8
- **[RCV000325492](https://www.ncbi.nlm.nih.gov/clinvar/RCV000325492/)**: not provided
- **[RCV000622347](https://www.ncbi.nlm.nih.gov/clinvar/RCV000622347/)**: Inborn genetic diseases
- **[RCV001836691](https://www.ncbi.nlm.nih.gov/clinvar/RCV001836691/)**: Parkinson disease, late-onset
- **[RCV003407254](https://www.ncbi.nlm.nih.gov/clinvar/RCV003407254/)**: LRRK2-related disorder
- **[RCV001195216](https://www.ncbi.nlm.nih.gov/clinvar/RCV001195216/)**: Young-onset Parkinson disease

    